Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 19, 2020
Event: Entry into a Material Definitive Agreement with the Cystic Fibrosis Foundation (CFF).
Key Financial Metrics and Obligations
This filing reports a specific funding agreement rather than periodic financial performance metrics (revenue, profit, cash flow, or margins are not disclosed in this document).
- Total Award Value: Up to $4,234,249.
- Previously Received: $484,249.
- Immediate Payment: $650,000 upon execution of the agreement.
- Remaining Funding: Incremental payments contingent on achieving development milestones.
- Royalty Cap: Maximum of 5 times the Award (approximately $21.2 million) payable upon commercialization.
- Milestone Royalties: Up to two additional payments of approximately $4.2 million each upon achieving specified net sales milestones.
Material Changes and Agreement Terms
The Company entered into a Therapeutic Development Award Agreement to support the preclinical development of MAT2501, a lipid nano-crystal oral formulation of amikacin for treating pulmonary non-tubercular mycobacteria infections.
- Payment Structure: Funding is milestone-based. The Company must make royalty payments to CFF contingent on commercialization, transfer, sale, licensing, or change of control.
- Termination: Either party may terminate for cause, including material failure to achieve milestones. Payment obligations survive termination.
- Financial Obligation: The agreement constitutes a direct financial obligation of the registrant as of November 19, 2020.
Guidance, Outlook, and Risks
Management Commentary: The agreement supports the Development Program for MAT2501. A press release announcing the award was issued on November 20, 2020.
Risks and Contingencies:
- Milestone Risk: Future funding is contingent on the achievement of specific development milestones.
- Commercialization Risk: Significant royalty obligations (up to ~$21.2 million cap plus milestone payments) are triggered only upon commercialization or specific sales thresholds.
- Termination Risk: The agreement can be terminated if the Company materially fails to achieve commercialization and development milestones.
Investor Verification Checklist
- Verify the specific development milestones required to unlock the remaining award funds.
- Confirm the exact net sales thresholds that trigger the additional $4.2 million milestone royalties.
- Review the full text of the Agreement (to be filed as an exhibit to the Form 10-K) for omitted terms and detailed indemnification provisions.
- Assess the Company's current cash position relative to the immediate $650,000 receipt and ongoing development costs.